Introduction {#S1}
============

Members of the family of the Enterobacteriaceae, although natural inhabitants of the intestinal tracts of mammals, may cause urinary tract, skin, ear, soft tissue, and respiratory infections in cats and dogs ([@B1]). For uncomplicated infections, first-line therapeutic options are ampicillin, amoxicillin-clavulanate or first- and second-generation cephalosporins, while amikacin, third-generation cephalosporins or fluoroquinolones (enrofloxacin or ciprofloxacin) remain appropriate for severe infections ([@B1], [@B2]). One of the most important mechanisms of antimicrobial resistance in Enterobacteriaceae is the enzymatic inactivation of penicillins and cephalosporins by means of plasmid-mediated extended-spectrum β-lactamases (ESBLs), such as the TEM-, SHV-, or cefotaxime (CTX)-M-group enzymes ([@B3]). The emergence of ESBL producing Enterobacteriaceae in healthy and in diseased companion animals constitutes an increasing challenge to infection management in veterinary therapy. Moreover, resistance caused by ESBLs is often associated with resistance to other classes of antibiotics like aminoglycosides, fluoroquinolones, and sulfamethoxazole/trimethoprim (SXT), which are antimicrobials that are critically important in human medicine ([@B4], [@B5]). Additionally, previous studies have shown that multidrug resistant, highly virulent human-related clonal lineages of Enterobacteriaceae, such as *Escherichia coli (E. coli)*, belonging to sequence type (ST)131 and ST648, or *Klebsiella pneumoniae (K. pneumoniae)* ST11, ST15, and ST147 may be isolated from companion animals ([@B6], [@B7]). Consequently, there is growing concern that ESBL producers in companion animals pose a potential health hazard to humans, either through direct transmission of resistant pathogens from animals to humans, or indirectly through transmission of resistance genes ([@B8], [@B9]). Recent data on the prevalence of ESBL producers in clinical isolates of cats and dogs and the phenotypes and genotypes of such isolates are scarce for Switzerland, and it remains unclear to what extent clinically relevant phylogenetic or clonal lineages occur.

Here, we analyze a collection of clinical feline and canine Enterobacteriaceae obtained during 2012--2016 by (i) identifying ESBL producers within the strain collection, (ii) assessing their antimicrobial resistance profiles, (iii) determining their *bla*~ESBL~ genes and screening for plasmid-mediated fluoroquinolone and azithromycin resistance genes, and by (iii) characterizing *E. coli* and *K. pneumoniae* strains by multilocus sequence typing (MLST), and *E. coli* strains by phylogenetic grouping and virulence gene profiling.

Materials and Methods {#S2}
=====================

Bacterial Isolates {#S2-1}
------------------

Between 2012 and 2016, 346 clinical Enterobacteriaceae were isolated from diseased cats (*n* = 115) and dogs (*n* = 231) admitted to the veterinary clinic of the University of Zürich. The isolates were cultured from urinary samples (*n* = 273), samples obtained from surgical sites (*n* = 26), abscess samples (*n* = 16), skin and skin wound samples (*n* = 14), bile samples (*n* = 7), and samples from other sites (*n* = 10). Strain identification and routine antimicrobial susceptibility profiling was performed using the VITEK^®^ two compact system with AST GN38 cards (Biomérieux, Nürtingen, Germany) according to the manufacturer's instructions. The identity of *Enterobacter cloaca*e (*E. cloacae*) was confirmed by matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF--MS, Bruker Daltronics, Bremen, Germany). ESBL producers were screened by using the chromogenic medium Brilliance™ ESBL Agar (Oxoid, Hampshire, UK), according to the manufacturer's recommendations. All non-duplicate isolates growing on ESBL agar were further analyzed. In accordance with local legislation, ethics approval was not required for this study.

Identification of *bla*~ESBL~ Genes and Antibiotic Susceptibility Testing {#S2-2}
-------------------------------------------------------------------------

The presence of *bla*~ESBL~ genes was established by PCR, and amplicons were sequenced as described previously using primers listed in Table S1 in Supplementary Material ([@B10]--[@B12]). For the detection of the CTX-M-25 enzyme group, the newly designed primers Gr. 25 CTX-M fw CCTGTGTTTCGCTGCTGTTGG and Gr. 25 CTX-M rv GGCTCTCTGCCTTCGGCTCC, were used.

Antimicrobial susceptibility testing was performed according to Clinical and Laboratory Standards Institute (CLSI) performance standards ([@B13]), using the disk-diffusion method and the antibiotics ampicillin (AM), amoxicillin with clavulanic acid (AMC), azithromycin (AZM), cefazolin, cefepime, CTX, chloramphenicol (C), ciprofloxacin (CIP), fosfomycin (FOS), gentamicin (G), kanamycin (K), nalidixic acid (NA), nitrofurantoin (F/M), streptomycin (S), SXT, and tetracycline (TE) (Becton Dickinson, Allschwil, Switzerland). Results were interpreted according to CLSI standards ([@B13]). For azithromycin, an inhibition zone of ≤12 mm was interpreted as resistant. Isolates displaying resistance to three or more classes of antimicrobials (counting β-lactams as one class) were defined as multidrug-resistant (MDR).

Identification of Additional Antimicrobial Resistance Genes {#S2-3}
-----------------------------------------------------------

The plasmid-mediated fluoroquinolone resistance genes *aac(6*\'*)-Ib-cr, qnrA, qnrB, qnrC, qnrD, qnrS*, and *qepA*, and the plasmid-mediated azithromycin resistance gene *mph(A)* were detected by PCR as described elsewhere using primers listed in Table S1 in Supplementary Material ([@B14], [@B15]).

Quinolone-resistant *E. coli* strains were examined for mutations in the quinolone resistance-determining regions (QRDRs) of *gyrA* and *parC*, using PCR amplification and sequencing primers as described previously using primers listed in Table S1 in Supplementary Material ([@B14]).

Synthesis of primers and DNA custom sequencing was carried out by Microsynth (Balgach, Switzerland) and nucleotide sequences were analyzed with CLC Main Workbench 6.6.1. For database searches, the BLASTN program of NCBI[^1^](#fn1){ref-type="fn"} was used.

Phylogenetic Characterization and MLST {#S2-4}
--------------------------------------

Phylogenetic classification of the *E. coli* isolates into one of the eight groups, including A, B1, B2, C, D, E, F, (*E. coli sensu stricto)*, or *Escherichia* clade I, was performed as described by Clermont et al. ([@B16]).

Sequence type determination of the *E. coli* isolates was carried out as described by Wirth et al. ([@B17]). Sequences were imported into the *E. coli* MLST database website[^2^](#fn2){ref-type="fn"} to determine MLST types. Alleles and STs that had not been previously described were termed new ST, but not assigned new numerical designations by the database.

Sequence type determination of the *K. pneumoniae* isolates was performed according to previously described methods ([@B18]). STs were determined according to the *Klebsiella* MLST database.[^3^](#fn3){ref-type="fn"}

Virulence Factor (VF) Determination in Uropathogenic *E. coli* Isolates {#S2-5}
-----------------------------------------------------------------------

*Escherichia coli* isolated from urinary samples were tested by conventional PCR for the presence of virulence-associated genes that mediate adhesion (*p*-fimbrial adhesion genes *papAH* and *papEF*, and the chaperone-usher fimbria *yfcv*), toxins (α-hemolysin *hlyA*), siderophores (the ferric yersiniabactin uptake protein *fyuA*), serum resistance (*traT*), and the right-hand terminus of pathogenicity island (PAI) from *E. coli* strain CFT073, using primers listed in Table S1 in Supplementary Material and conditions described previously ([@B19], [@B20]). The aggregate VF score was defined as the number of unique VF detected for each isolate, counting the PAI marker as one.

Results {#S3}
=======

During 2012--2016, 20.8% (72/346) of clinical Enterobacteriaceae isolated from cats and dogs were ESBL producers. The isolates originated from 7 cats and 65 dogs, amounting to 6% (7/115) of the feline and 28.1% (65/231) of the canine isolates, respectively. The prevalence of ESBL producers was remarkably higher among isolates from dogs than from cats. Overall, ESBL producers (58 *E. coli*, 11 *K. pneumoniae*, and 3 *E. cloacae*) were cultured from 16.5% (45/273) of the urinary samples, 57.1% (8/14) of the skin and skin wound samples, 37.5% (6/16) of abscess samples, 23% (6/26) of the samples obtained from surgical sites, 57.1% (4/7) of bile samples, and 30% (3/10) of the samples from other sites (Table [1](#T1){ref-type="table"}). Among the *E. coli* from urinary samples, 17% (35/205) were ESBL producers (Table [1](#T1){ref-type="table"}).

###### 

Percent and distribution of extended-spectrum β-lactamases (ESBL) producers among clinical Enterobacteriaceae from cats and dogs in Switzerland, 2012--2016.

  **Host**   **Source**       *Escherichia coli*   *Klebsiella pneumoniae*   *Enterobacter cloacae*   Other species[^a^](#tfn1){ref-type="table-fn"}   Total Enterobacteriaceae                                                
  ---------- ---------------- -------------------- ------------------------- ------------------------ ------------------------------------------------ -------------------------- ------ ---- --- ---- ---- --- --- ----- ---- ------
  Cats       Urine            74                   1                         1.4                      6                                                2                          33.3   10   0   0    6    0   0   96    3    3.1
  Cats       Surgical sites   4                    1                         25                       0                                                0                          0      2    0   0    0    0   0   6     1    16.6
  Cats       Abscess          3                    1                         33.3                     0                                                0                          0      2    0   0    0    0   0   5     1    20
  Cats       Wound/skin       3                    1                         33.3                     0                                                0                          0      0    0   0    0    0   0   3     1    33.3
  Cats       Bile             3                    0                         0                        0                                                0                          0      0    0   0    0    0   0   3     0    0
  Cats       Other            2                    1                         50                       0                                                0                          0      0    0   0    0    0   0   2     1    50
  Dogs       Urine            131                  34                        26                       25                                               5                          20     10   3   30   11   0   0   177   42   23.7
  Dogs       Surgical sites   13                   5                         38.5                     3                                                0                          0      4    0   0    0    0   0   20    5    25
  Dogs       Abscess          6                    4                         66.7                     3                                                1                          33.3   0    0   0    2    0   0   11    5    45.5
  Dogs       Wound/skin       6                    5                         83.3                     2                                                2                          100    1    0   0    2    0   0   11    7    63.6
  Dogs       Bile             4                    4                         100                      0                                                0                          0      0    0   0    0    0   0   4     4    100
  Dogs       Other            5                    1                         20                       1                                                1                          100    2    0   0    0    0   0   8     2    25

*^a^Other species included Citrobacter freundii, Citrobacter koseri, Proteus mirabilis, and Proteus vulgaris*.

In addition to their resistance to penicillins and extended-spectrum cephalosporins, the isolates were frequently resistant to quinolones and fluoroquinolones, with 88.9% (64/72) resistant to NA and 83.3% (60/72) resistant to ciprofloxacin. They were also resistant to SXT (76.4%, 55/72), TE (72.2%, 52/72), aminoglycosides streptomycin (45.8%, 33/72), gentamycin (37.5%, 27/72), kanamycin (19.4%, 14/72), chloramphenicol (25%, 18/72), as well as to azithromycin (22.2%, 16/72), and to nitrofurantoin (12.5%, 9/72). One *K. pneumoniae* isolate (1.4%) was resistant to fosfomycin. Overall, 73.6% (53/72) were MDR and none was pansusceptible (Table S2 in Supplementary Material).

In total, 73 ESBL genes were detected among the 72 isolates, including in 1 *K. pneumoniae* isolate co-harboring *bla*~CTX-M-15~ and *bla*~SHV-12~ (Table [2](#T2){ref-type="table"}). Among the ESBL genes, *bla*~CTX-M-15~ predominated (54.8%, 40/73), followed by *bla*~CTX-M-1~ (24.7%, 18/73). Other ESBL genes included *bla*~CTX-M-55~ (6.8%, 5/73), *bla*~CTX-M-14~ and *bla*~SHV-12~ (each 5.5%, 4/73), and *bla*~CTX-M-27~ (2.7%, 2/73).

###### 

Type and distribution of extended-spectrum β-lactamases (ESBL) genes and other plasmid-mediated resistance genes among 72 clinical Enterobacteriaceae isolated from cats and dogs in Switzerland, 2012--2016.

  Host   Species                                   No. of isolates   Source (*n*)                                                                MLST (*n*)                                                        *bla*~ESBL~                      Additional plasmid-mediated AMR determinants
  ------ ----------------------------------------- ----------------- --------------------------------------------------------------------------- ----------------------------------------------------------------- -------------------------------- ----------------------------------------------
  Cat    *Escherichia coli (E. coli)*              1                 Urine (1)                                                                   10 (1)                                                            *bla*~CTX-M-1~                   −
  Cat    *E. coli*                                 1                 Other (1)                                                                   23 (1)                                                            *bla*~CTX-M-1~                   *mph(A), qnrS*
  Cats   *E. coli*                                 3                 Abscess (1), wound (1), surgical site (1)                                   361 (2), 648 (1)                                                  *bla*~CTX-M-15~                  *mph(A), aac(6*\'*)-Ib-cr*
  Cat    *Klebsiella pneumoniae (K. pneumoniae)*   1                 Urine (1)                                                                   15 (1)                                                            *bla*~CTX-M-15~                  *aac(6*\'*)-Ib-cr*
  Cat    *K. pneumoniae*                           1                 Urine (1)                                                                   147 (1)                                                           *bla*~CTX-M-15~                  *qnrS*
  Dogs   *E. coli*                                 13                Urine (9), abscess (1), wound (1), surgical site (2)                        58 (1),101 (2), 117 (1), 410 (5), 617 (2), 1431 (1), new ST (1)   *bla*~CTX-M-1~                   −
  Dog    *E. coli*                                 1                 Surgical site (1)                                                           3,889 (1)                                                         *bla*~CTX-M-1~                   *mph(A)*,
  Dog    *E. coli*                                 1                 Bile (1)                                                                    90 (1)                                                            *bla*~CTX-M-1~                   *mph(A), aac(6*\'*)-Ib-cr*
  Dog    *K. pneumoniae*                           1                 Urine (1)                                                                   788 (1)                                                           *bla*~CTX-M-1~                   *mph(A), qnrB*
  Dogs   *E. coli*                                 2                 Urine (2)                                                                   744 (2)                                                           *bla*~CTX-M-14~                  −
  Dogs   *E. coli*                                 2                 Urine (1), wound (1)                                                        744 (1), 131 (1)                                                  *bla*~CTX-M-14~                  *mph(A)*
  Dogs   *E. coli*                                 3                 Urine (3)                                                                   131 (1), 354 (1), 648 (1)                                         *bla*~CTX-M-15~                  −
  Dog    *E. coli*                                 1                 Urine (1)                                                                   533 (1)                                                           *bla*~CTX-M-15~                  *mph(A)*
  Dogs   *E. coli*                                 10                Urine (7), bile (1), wound (1), surgical site (1)                           131 (3), 410 (7)                                                  *bla*~CTX-M-15~                  *aac(6*\'*)-Ib-cr*
  Dogs   *E. coli*                                 12                Urine (5), abscess (3), bile (1), wound (1), surgical site (1), other (1)   131 (1), 167 (2), 361 (6), 410 (2), new ST (1)                    *bla*~CTX-M-15~                  *mph(A), aac(6*\'*)-Ib-cr*
  Dog    *E. coli*                                 1                 Urine (1)                                                                   New ST (1)                                                        *bla*~CTX-M-15~                  *mph(A), aac(6*\'*)-Ib-cr, qnrB*
  Dogs   *K. pneumoniae*                           4                 Urine (3), other (1)                                                        147 (4)                                                           *bla*~CTX-M-15~                  *qnrS*
  Dogs   *K. pneumoniae*                           2                 Wound (2)                                                                   15 (2)                                                            *bla*~CTX-M-15~                  *aac(6*\'*)-Ib-cr*
  Dog    *K. pneumoniae*                           1                 Abscess (1)                                                                 11 (1)                                                            *bla*~CTX-M-15~                  *mph(A), aac(6*\'*)-Ib-cr, qnrB*
  Dog    *K. pneumoniae*                           1                 Urine (1)                                                                   147 (1)                                                           *bla*~CTX-M-15~, *bla*~SHV-12~   *qnrS*
  Dog    *E. coli*                                 1                 Urine (1)                                                                   131 (1)                                                           *bla*~CTX-M-27~                  *mph(A)*
  Dog    *E. coli*                                 1                 Bile (1)                                                                    648 (1)                                                           *bla*~CTX-M-27~                  *mph(A), aac(6*\'*)-Ib-cr*
  Dogs   *E. coli*                                 3                 Urine (2), wound (1)                                                        457 (2), 1177 (1)                                                 *bla*~CTX-M-55~                  −
  Dogs   *E. coli*                                 2                 Urine (2)                                                                   410 (2)                                                           *bla*~CTX-M-55~                  *mph(A), aac(6*\'*)-Ib-cr*
  Dogs   *Enterobacter cloacae*                    3                 Urine (3)                                                                   --                                                                *bla*~SHV-12~                    *qnrA*

*aac(6')-Ib-cr, aminoglycoside 6′-N-acetyltransferase variant; AMR, antimicrobial resistance; bla, β-lactamase gene; MLST, multilocus sequence typing; mph(A), macrolide 2′-phosphotransferase gene; qnr, quinolone resistance gene; --, not determined; −, not present*.

In addition to *bla*~ESBLs~, other plasmid-mediated resistance genes detected among the 72 isolates included *aac(6*'*)-Ib*-cr (47.2%, 34/72), *mph(A)* (38.9%, 28/72), *qnrS* (9.7%, 7/72), *qnrA* and *qnrB* (each 4.2%, 3/72) (Table [2](#T2){ref-type="table"}).

The majority of the *aac(6*'*)-Ib-cr* genes (88.2%, 30/34), the *mph(A)* genes (62%, 18/29), the *qnrB* (66.7%, 2/3), and *qnrS* genes (85.7%, 6/7) was detected in isolates harboring *bla*~CTX-M-15~. All *qnrA* were detected together with *bla*~SHV-12~ in *E. cloacae* (Table [2](#T2){ref-type="table"}).

Phylogenetic analysis of the 58 *E. coli* isolates revealed a predominance of group C (32.8%, 19/58), followed by group A (31%, 18/58), group B2 and group F (each 12%, 7/58), group B1 (8.6%, 5/58), and group D (3.4%, 2/58) (Table S2 in Supplementary Material).

Among the 58 *E. coli* isolates, 23 different STs and three new STs were identified (Table [2](#T2){ref-type="table"}; Table S3 in Supplementary Material). Most frequently, isolates belonged to ST410 (27.6%, 16/58), followed by a collective of STs occurring only once or twice (24.1%, 14/58), ST361 (13.8%, 8/58), ST131 (12%, 7/58), and ST648, ST744, and new STs (each 5.2%, 3/58). *E. coli* ST410 and human-related pandemic clone *E. coli* ST131 were detected only in isolates from dogs. *E. coli* ST410 was isolated from 33.3% of the urine samples from dogs.

Among the 11 *K. pneumoniae* isolates, 4 different STs were detected (Table [2](#T2){ref-type="table"}; Table S2 in Supplementary Material). The majority (54.5%, 6/11) of the isolates belonged to ST147. Other STs included ST15 (27.3%, 3/11), ST11, and ST788 (both 9.1%, 1/11).

Among the 51 *E. coli* isolates displaying quinolone resistance, all revealed chromosomal mutations that result in amino acid substitutions in GyrA and ParC. Unusual point mutations Asp87→Tyr in GyrA and Glu84→Gly in ParC were noted for two *E. coli* ST457 isolates harboring *bla*~CTX-M-55~ (Table [3](#T3){ref-type="table"}; Table S2 in Supplementary Material).

###### 

Amino acid substitutions in the QRDR of 51 quinolone-resistant extended-spectrum β-lactamases producing *Escherichia coli* from cats and dogs in Switzerland, 2012--2016.

  Host (*n* = 51)   QRDR                                                    
  ----------------- ---------- ----------- --------- ----------- ---------- ---------
  Cats (*n* = 4)    4 (100)    3 (75)      0 (0)     0 (75)      0 (0)      0 (0)
  Dogs (*n* = 47)   47 (100)   44 (93.6)   2 (4.3)   46 (97.9)   7 (14.9)   1 (2.1)

*Asn, asparagine; Asp, aspartic acid; CIP, ciprofloxacin; Glu, glutamic acid; Gly, glycine; *gyrA*, DNA gyrase (type II topoisomerase) gene; Ile, isoleucine; Leu, leucine; *parC*, topoisomerase IV gene; QRDR, quinolone resistance determining region; Ser, serine; Tyr, tyrosine; Val, valine*.

Virulence factors were distributed unequally among the 35 uropathogenic *E. coli* isolates (Table [4](#T4){ref-type="table"}).

###### 

Virulence-associated genes detected in 35 uropathogenic extended-spectrum β-lactamases producing *Escherichia coli* from cats and dogs in Switzerland, 2012--2016.

  Host   No. of isolates   PG   ST     CC    *papAH*   *papEF*   *yfcv*   *hlyA*   *fyuA*   *traT*   PAI   Plasmid-mediated resistance gene(s)
  ------ ----------------- ---- ------ ----- --------- --------- -------- -------- -------- -------- ----- --------------------------------------------------
  Dog    1                 A    617    10    \+        \+        −        \+       \+       \+       \+    *bla*~CTX-M-1~
  Dog    1                 A    617    10    \+        \+        −        −        \+       \+       \+    *bla*~CTX-M-1~
  Dog    2                 A    361    --    −         −         −        −        −        −        −     *aac(6*\'*)-Ib-cr, bla*~CTX-M-15~, *mph(A)*
  Dog    1                 A    361    --    −         −         −        −        \+       \+       −     *aac(6*'*)-Ib-cr, bla*~CTX-M-15~, *mph(A)*
  Dog    1                 A    744    --    --        −         −        −        −        \+       −     *mph(A), bla*~CTX-M-14~
  Dog    2                 A    744    --    −         −         −        −        −        −        −     *bla*~CTX-M-14~
  Dog    1                 B1   533    --    −         −         −        −        −        \+       −     *mph(A), bla*~CTX-M-15~
  Dog    1                 B1   1431   --    −         −         −        \+       \+       \+       −     *bla*~CTX-M-1~
  Dog    2                 B2   131    131   \+        \+        \+       \+       \+       \+       \+    *aac(6*'*)-Ib-cr, bla*~CTX-M-15~
  Dog    1                 B2   131    131   \+        \+        \+       \+       \+       \+       \+    *bla*~CTX-M\ 15~
  Dog    1                 B2   131    131   −         −         \+       −        \+       \+       \+    *mph(A), bla*~CTX-M-27~
  Cat    1                 C    23     23    −         −         −        −        \+       −        −     *bla*~CTX-M-1~
  Dog    5                 C    410    23    −         −         −        −        −        −        −     *bla*~CTX-M-1~
  Dog    5                 C    410    23    −         −         −        −        −        −        −     *aac(6*'*)-Ib-cr, bla*~CTX-M-15~
  Dog    1                 C    410    23    \+        −         −        −        \+       −        −     *aac(6*'*)-Ib-cr, bla*~CTX-M-15~, *mph(A)*
  Dog    1                 C    410    23    −         −         −        −        −        −        −     *aac(6*'*)-Ib-cr, bla*~CTX-M-15~, *mph(A)*
  Dog    2                 C    410    23    −         −         −        \+       −        −        −     *aac(6*'*)-Ib-cr, bla*~CTX-M-55~, *mph(A)*
  Dog    1                 C    nd     nd    −         −         −        \+       −        −        −     *aac(6*'*)-Ib-cr, bla*~CTX-M-15~, *mph(A), qnrB*
  Dog    1                 D    1177   --    −         −         −        −        \+       \+       −     *bla*~CTX-M-55~
  Dog    1                 F    117    --    −         −         −        −        −        \+       −     *bla*~CTX-M-1~
  Dog    1                 F    354    354   −         −         \+       −        −        \+       −     *bla*~CTX-M-15~
  Dog    1                 F    457    --    −         −         \+       −        −        \+       \+    *bla*~CTX-M-55~
  Dog    1                 F    648    648   −         −         \+       −        \+       \+       \+    *bla*~CTX-M-15~

*aac(6')-Ib-cr, aminoglycoside 6\'-N-acetyltransferase variant; bla, β-lactamase gene; CC, clonal complex; fyuA, ferric yersiniabactin uptake protein gene; hlyA, α-hemolysin gene; mph(A), macrolide 2′-phosphotransferase gene; nd, not determined; PAI, right-hand terminus of pathogenicity island; papAH and papEF, p-fimbrial adhesion genes; PG, phylogenetic group; qnrB, quinolone resistance gene; ST, sequence type; traT, serum resistance gene; yfcv, chaperone-usher fimbria gene; +, presence of a trait; −, absence of a trait; --, not applicable*.

For 42.9% (15/35) of *E. coli* urinary isolates, no VF was detected. Strains with aggregate VF score ≥1 were identified in 34.5% (57.1%/35) of the isolates. VF scores were highest for isolates belonging to ST617 (median 5.5, range 5--6) and ST131 (median 7, range 4--7).

Discussion {#S4}
==========

This study identified a high prevalence (20.8%) of ESBL-producing Enterobacteriaceae derived from clinical samples of cats and dogs collected during 2012--2016 at the veterinary clinic of the University of Zürich, Switzerland. This is considerably higher than that found in similar studies from pets in the UK (7%) ([@B21]), the Netherlands (2%) ([@B22]), and France (3.7%) ([@B23]), and remarkably higher than the prevalence of 1.6% detected in a European collection of Enterobacteriaceae obtained from diseased companion animals in 2015 ([@B6]). In addition, among the uropathogenic *E. coli* analyzed in this study, the observed prevalence of 16.8% of ESBL producers is considerably higher than that found previously in cats and dogs in Switzerland between 2010 and 2012 (7.5%) ([@B24]). Although our data are single-institution based and thus limited, they provide important information on the trends in the burden of infections due to ESBL producers in veterinary medicine in Switzerland.

Overall, a diversity of *bla*~ESBL~ genes was found within three bacterial species. The predominance of *bla*~CTX-M-15~, which is highly prevalent in ESBL producers in humans, is comparable to what is found in other studies on isolates from companion animals ([@B21], [@B23], [@B25]). This gene was the only one that was detected in cats and dogs in Switzerland between 2010 and 2012 ([@B24]). Our study shows that in the following years, *bla*~CTX-M-1~, *bla*~CTX-M-14~, *bla*~CTX-M-27~, *bla*~CTX-M-55~, and *bla*~SHV-12~ harboring Enterobacteriaceae have emerged in cats and dogs in Switzerland.

Second to *bla*~CTX-M-15~, *bla*~CTX-M-1~ was the most frequent variant identified in this study. The *bla*~CTX-M-1~ gene is the most prevalent *bla*~ESBL~ gene among ESBL-producing Enterobacteriaceae isolated food-producing animals and food, in particular chicken and chicken meat ([@B26], [@B27]). Consumption of raw meat represents a risk factor for dogs acquiring pathogenic *E. coli*, including ESBL producers ([@B28], [@B29]). Moreover, a recent study detected a high prevalence (77.8%) of ESBL producers in raw cat food and demonstrated a strong association of consumption of raw cat food with shedding of ESBL producers by household cats in the Netherlands ([@B30]). Further studies are needed to investigate the possibility of raw meat as an origin of the high prevalence of ESBL and the occurrence of CTX-M-1 producers in isolates from companion animals in Switzerland. Similarly, CTX-M-55 has been widely reported in food-producing animals and pets in mainland China ([@B31]). This ESBL variant has rarely been detected outside China and its emergence in pets in Switzerland, possibly due to international food and animal trade, warrants attention.

This study identified 17 (23.6%) isolates belonging to major lineages of human pathogenic *K. pneumoniae* and *E. coli*. CTX-M-15 producing *K. pneumoniae* ST11, ST 15, and ST147 represent major international high-risk nosocomial clones ([@B32]). *K. pneumoniae* ST11 and ST15 from companion animals have been involved in nosocomial events in veterinary clinics ([@B7], [@B33]). By contrast, *K. pneumoniae* ST147 has only very recently been detected in pets in Europe and in Japan ([@B34], [@B35]), and this is to our knowledge the second report on this ST isolated from dogs in Europe.

Pandemic human pathogenic *E. coli* ST131-producing CTX-M-15 has disseminated globally in hospital and community settings causing a wide spectrum of infections, including urinary tract infection, cystitis, pyelonephritis, and bacteremia, with transmission between humans and their companion animals (cats and dogs in particular) was well documented ([@B36]). Since the earlier study period 2010--2012 ([@B24]), the prevalence of ESBL-producing uropathogenic *E. coli* ST131 among feline and canine samples in Switzerland has increased from 0 to 1.5% (4/273), and includes *E. coli* ST131-CTX-M-15 as well as ST131-CTX-M-27, which is currently emerging in human medicine in Germany, France, and Japan ([@B37], [@B38]).

Other human-related strains detected in this study included *E. cloacae* harboring *bla*~SHV-12~ together with the plasmid-mediated quinolone resistance gene *qnrA*. The combined presence of *bla*~SHV-12~ and *qnrA* has been described in human clinical *E. cloacae* isolates in hospitals in France and the UK ([@B39], [@B40]). Although data on ESBL-producing *E. cloacae* in animals are scarce ([@B22], [@B41]), our results provide evidence that this important pathogen has emerged in companion animals in Switzerland, illustrating their potential for increased dissemination.

In this study, the identification of phylogenetic groups among the *E. coli* isolates was performed based on the new Clermont scheme ([@B16]). Consequently, a number of STs from this study were classified as phylogenetic group F from their original D designation, including *E. coli* ST117 which is a recognized avian pathogenic lineage ([@B42]), *E. coli* ST354 and ST648, which are frequently detected in humans and animals ([@B9], [@B43]), and the rarely described *E. coli* ST457. In this study, we detected two isolates belonging to ST457, both harboring the uncommon *bla*~CTX-M-55~. *E. coli* ST457-CTX-M-55 harboring the carbapenemase gene *bla*~KPC-3~ was isolated in Italy from a human diagnosed with pneumonia ([@B44]), but to our knowledge, this ST has not been associated with disease in companion animals before.

A large number (26.4%, 19/72) of isolates changed designation from the original phylogenetic group A to group C. Most isolates in this group belonged to ST410 and were of low virulence. However, the panel of VFs selected for this study was limited in number and represents only a subset of known VFs. Other important determinants of virulence may have been missed due to this limitation. Nevertheless, the pathogenic potential of ST410 has been documented previously, together with strong evidence for clonal dissemination of *E. coli* ST410 between the avian wildlife, humans, and companion animals in Germany ([@B45], [@B46]). CTX-M-15-producing *E. coli* ST410 was also identified as a veterinary hospital strain in the UK ([@B21]). Although currently available reports on *bla*~ESBLs~ in ST410 are limited to *bla*~CTX-M-15~, our results demonstrate that this ST can also harbor *bla*~CTX-M-1~ and *bla*~CTX-M-55~, both variants that occur among food-producing animals ([@B26], [@B31]). Here, we provide further evidence for the pathogenic potential of this ST in companion animals and suggest that, in addition to its potential as an international clone for the dissemination of *bla*~CTX-M-15~, it may contribute to the dispersion of other resistance genes, including other *bla*~ESBL~ variants, *aac(6*'*)-Ib-cr*, and *mph(A)*. The high prevalence (38.9%) of isolates harboring plasmid-mediated *mph(A)* which confers reduced susceptibility to azithromycin is of concern, since this macrolide is considered a last-resort antimicrobial agent for shigellosis ([@B47]). Furthermore, azithromycin represents an option for the treatment of Gram-negative rods expressing MDR, including carbapenem-resistant isolates of *Pseudomonas aeruginosa, K. pneumoniae*, and *Acinetobacter baumannii* ([@B48]), and is the only antimicrobial under consideration for the treatment of enterohemorrhagic *E. coli* in humans ([@B49]).

In conclusion, this study provides information on the prevalence, the *bla*~ESBL~ variants and the genotypes of ESBL-producing isolates in cats and dogs in Switzerland. The occurrence of potentially high-risk human-related *K. pneumoniae* and *E. coli* clones, as well as *E. cloacae* harboring *bla*~SHV-12~ and *qnrA* genes, previously described in humans suggests transmission events between companion animals as well as the possibility of the presence of a common source. This collection of ESBL-producing Enterobacteriaceae from cats and dogs identifies *E. coli* phylogroup C ST410 as a frequent MDR, ESBL-producing clone among clinical isolates from dogs in Switzerland that warrants further attention. The clinical significance of phylogroup C strains as etiological agents of extraintestinal disease and disseminators of antimicrobial resistance in companion animals remains to be investigated. Understanding the epidemiological and molecular features of ESBL-producing Enterobacteriaceae in companion animals can be helpful for infection management and prevention in veterinary as well as in human medicine.
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